Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Natural Killer T-Cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies

NCT03774654 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT03774654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03774654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Natural Killer T-Cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 14, 2020
Completion date
May 5, 2040
Enrollment
13 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

refractory b-cell non-hodgkin lymphoma, refractory b-cell small lymphocytic lymphoma, relapsed adult all, relapsed cll, relapsed non hodgkin lymphoma